STEAP1 (Six transmembrane epithelial antigen of the prostate 1) is a member of the six-transmembrane epithelial antigen family encoded by the STEAP1 gene and is primarily localized on the cell membrane surface. STEAP1 is highly expressed in multiple solid tumors, including prostate cancer, Ewing sarcoma, bladder cancer, and lung cancer, while its expression in normal tissues is relatively restricted ^[1-3]. STEAP1 is involved in biological processes including cell proliferation, redox homeostasis, and regulation of the tumor microenvironment, and has been associated with tumor invasion, metastasis, and poor prognosis in multiple malignancies ^[2-4]. Due to its tumor-associated high expression pattern and membrane localization, STEAP1 is considered an important target for cancer immunotherapy. Studies involving STEAP1-targeted monoclonal antibodies, antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and CAR-T/CAR-NK cell therapies have been reported ^[3-5]. The huSTEAP1 mouse is a humanized model generated by replacing the sequence of exons 2 to 5 in the murine Steap1 gene with the corresponding sequence of human STEAP1 exons 2 to 5. This model is suitable for evaluating the in vivo efficacy and safety of STEAP1-targeted therapeutics, including monoclonal antibodies, ADCs, TCEs, and CAR-T/CAR-NK cells. Furthermore, it is applicable to research on the pathogenesis of prostate cancer and other STEAP1-overexpressing tumors, as well as studies on the tumor immune microenvironment and combination therapy strategies.